Dr. Halle Moore discusses the long-term results of the OlympiA trial presented at the San Antonio Breast Cancer Symposium. The study observed patients with BRCA mutations and high-risk HER2-negative breast cancer treated with adjuvant olaparib after chemotherapy. Results showed continued benefits of adjuvant olaparib for patients with BRCA mutations and no increased risk of myelodysplasia or acute leukemia. The study provides promising results for the use of olaparib in the adjuvant setting. Published at the San Antonio Breast Cancer Symposium in December 2024, the study highlights the potential benefits of olaparib for certain breast cancer patients.
Source link
OlympiA trial shows olaparib’s benefits for patients with BRCA mutations ‘persist’
